Today: 7 February 2026
Subscribe
Browse Category

Pharmaceutical Industry News 29 January 2026 - 5 February 2026

Cigna stock jumps as earnings beat meets soft 2026 outlook and FTC insulin settlement

Cigna stock jumps as earnings beat meets soft 2026 outlook and FTC insulin settlement

Cigna shares rose 3.2% to $280.46 after posting Q4 adjusted earnings of $8.08 per share, above forecasts, though its 2026 outlook missed estimates. Express Scripts agreed to a 10-year FTC settlement on insulin pricing, expected to cut patient costs by up to $7 billion. Evernorth pharmacy revenue jumped 20% to $36.3 billion. Cigna’s board raised its quarterly dividend to $1.56 per share.
5 February 2026
·····
Eli Lilly stock jumps as 2026 forecast beats estimates on Zepbound, Mounjaro demand

Eli Lilly stock jumps as 2026 forecast beats estimates on Zepbound, Mounjaro demand

Eli Lilly shares surged about 9% Wednesday after reporting a 43% jump in quarterly revenue to $19.3 billion and issuing a bullish 2026 outlook. Mounjaro and Zepbound drove results, but executives warned pricing will weigh on future growth. Investors await the FDA’s April decision on Lilly’s oral obesity drug. The stock’s rally contrasted with declines in major indexes.
4 February 2026
····
Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer stock price jumps as once‑monthly obesity shot data lands; June readout in focus

Pfizer shares rose 3.7% to $26.73 Wednesday after reporting Phase 2b trial results showing up to 12.3% placebo-adjusted weight loss at 28 weeks for its obesity drug PF’3944. The company reaffirmed its 2026 revenue and profit targets and said it will not pursue share buybacks. Pfizer reported Q4 adjusted EPS of 66 cents on $17.6 billion revenue. Full VESPER-3 results will be released June 6.
4 February 2026
····
Veradermics IPO Pops Above Range as Eli Lilly Lines Up a 5% Stake Play

Veradermics IPO Pops Above Range as Eli Lilly Lines Up a 5% Stake Play

Veradermics priced its upsized IPO at $17 per share, raising about $256.3 million ahead of its NYSE debut under the ticker “MANE” on Feb. 4. Eli Lilly disclosed plans to acquire up to 4.9% of post-IPO shares, though the move is not binding. Veradermics sold 15,077,647 new shares, valuing the company at roughly $596 million.
4 February 2026
·····
Zurich’s £8bn Beazley bid jolts FTSE 100 to a fresh record as GSK rallies, AI fears hit data stocks

Zurich’s £8bn Beazley bid jolts FTSE 100 to a fresh record as GSK rallies, AI fears hit data stocks

Zurich Insurance has proposed to buy Beazley for up to 1,335 pence per share, valuing the deal at about £8 billion. Beazley’s board said it would support the offer if Zurich makes a firm bid by Feb. 16. Beazley shares rose 9% on the news. The FTSE 100 hit a new intraday high, with GSK up and Relx and LSEG under pressure from AI concerns.
4 February 2026
·····
AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie stock ticks up ahead of earnings after Rinvoq vitiligo filing—what investors watch next

AbbVie shares rose 0.8% to $227.55 Tuesday afternoon ahead of its quarterly earnings report due Wednesday morning. The company filed with U.S. and European regulators to expand Rinvoq’s use to non-segmental vitiligo, based on Phase 3 data. Investors are watching whether new immunology drugs can offset Humira’s sales decline.
3 February 2026
····
Why Johnson & Johnson stock is up today: new Varipulse Plus update puts AFib data back in play

Why Johnson & Johnson stock is up today: new Varipulse Plus update puts AFib data back in play

Johnson & Johnson shares rose about 1.4% to $233.87 Tuesday after unveiling new pulsed-field ablation and imaging technologies ahead of the AF Symposium. The company will present Omny-AF pilot data on Feb. 6 and its stock will trade ex-dividend on Feb. 24. Medtronic announced a $585 million CathWorks acquisition as PFA competition intensifies.
3 February 2026
·····
Novo Nordisk stock slides as broker cuts rating ahead of Feb. 4 earnings

Novo Nordisk stock slides as broker cuts rating ahead of Feb. 4 earnings

Novo Nordisk shares fell 1.6% to 363.7 Danish crowns in Copenhagen after ABG Sundal Collier downgraded the stock to “hold” and cut its price target to 350 crowns. The move comes ahead of the company’s Feb. 4 earnings report, with analysts expecting a drop in quarterly operating profit to 31.47 billion crowns.
2 February 2026
·····
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio shares (IBRX) closed Friday up 6% at $6.25, bucking broader market declines. The company faces dilution risk after amending a $505 million convertible note with Nant Capital. Attention is on FDA feedback for ANKTIVA’s label expansion in papillary bladder cancer, with a regulatory submission expected within 30 days. The next major event is the late-February ASCO GU conference.
1 February 2026
·····
Merck stock jumps to $110 as MRK heads into a big earnings week

Merck stock jumps to $110 as MRK heads into a big earnings week

Merck shares rose 1.8% to $110.27 Friday, outperforming a falling S&P 500 and closing about 2% below their 52-week high. Trading volume topped 19 million shares, well above rivals. Investors await Merck’s Feb. 3 earnings call and new inflation data that could affect rate expectations. Markets reacted to President Trump’s Fed pick and mixed inflation signals.
31 January 2026
·····
Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials

Denali Therapeutics shares rose 3.7% to $21.62 Thursday after the FDA halted Regenxbio’s gene therapy trials over a brain tumor case, intensifying focus on Denali’s Hunter syndrome drug under FDA review. Investors await Denali’s clinical data update in early February and a regulatory decision by April 5. The iShares Nasdaq Biotechnology ETF was little changed.
29 January 2026
·····
1 2 3 … 12

Stock Market Today

iFAST share price drops 3% as markets shut; earnings next week in focus

iFAST share price drops 3% as markets shut; earnings next week in focus

7 February 2026
iFAST shares fell 3.2% to S$9.64 in heavy trading Friday, closing near the day’s low as investors awaited FY2025 results due Feb. 12. The stock is about 13% below its 52-week high. iFAST recently agreed to buy a 30% stake in Financial Alliance for S$19.6 million, pending regulatory approval. Assets under administration stood at S$30.62 billion as of Sept. 30.
Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

Sembcorp Industries share price: what to watch after Friday dip as Feb 25 results near

7 February 2026
Sembcorp shares closed at S$6.05 on Friday, down 0.33%, as Singapore’s STI dropped 0.8%. Shareholders approved the A$6.5 billion Alinta Energy takeover on Jan 30, but the deal still faces regulatory and closing conditions. Sembcorp will release FY2025 results on Feb 25 before market open. Trading volume reached about 4.3 million shares.
Hongkong Land share price drops 4% despite fresh buyback — what investors watch next

Hongkong Land share price drops 4% despite fresh buyback — what investors watch next

7 February 2026
Hongkong Land shares fell 4.2% to US$8.18 in Singapore on Friday after the company disclosed a buyback of 170,000 shares at US$8.5252 each on Feb. 5, with plans to cancel them. The drop followed a volatile week marked by a new Singapore real estate fund launch and an expanded buyback programme. Investors are watching for the group’s annual results on March 5.
Go toTop